#### **Pituitary Disorders**


Aishah Ekhzaimy, MBBS, FRCPC, FACE

Endocrine & Metabolism Unit, Department of Medicine King Saud University


#### Objectives

- To understand basic pathophysiology and feedback for pituitary hormones.
- Know about clinical approach for common anterior pituitary gland disorders:
  - Common clinical presentations.
  - Main laboratory investigations.
  - Radiological investigations
  - Describe lines of management for each of these conditions.

## **Endocrine system**



# Pituitary Gland



#### Pituitary Development

#### **ANTERIOR PITUITARY**


- Rathke's pouch,
   Ectodermal evagination of oropharynx
- Synthesis and secrete
  - (GH,LH,FSH,PRL,TSH,ACTH)
- recognizable by 4- 5<sup>th</sup> wk of gestation and full maturation by 20<sup>th</sup> wk
- Portion of Rathke's pouch →→
   Intermediate lobe
- Remnant of Rathke's pouch cell in oral cavity →→ pharyngeal pituitary

#### POSTERIOR PITUITARY (NEUROHYPOPHYSIS)

- neural cells as an outpouching from the floor of 3<sup>rd</sup> ventricle
- Only storage:
  - Oxyctocin, ADH (hypothalamic hormones)

#### Sella turcica


- Lies at the base of the skull
- Roof: diaphragma sellae
  - Pituitary stalk and its blood vessels pass through the diaphragm
- Floor: Sphenoid sinus
- <u>Lateral walls:</u> cavernous sinus
  - containing III, IV, VI, V1, V2 cranial nerves and internal carotid artery with sympathetic fibers.
  - Both adjacent to temporal lobes



### Pituitary Development


- Pituitary stalk in midline joins the pituitary gland with hypothalamus that is below 3<sup>rd</sup> ventricle
- Development of pituitary cells is controlled by a set of transcription growth factors like
  - Pit-1, Prop-1, Pitx2

## Pituitary Development



- Pituitary gland measures
  - 15 X 10 X 6 mm, weighs 500 mg but about 1 g in women
- Optic chiasm
  - lies 10 mm above the gland and anterior to the stalk
- Blood supply :
  - superior, middle, inferior hypophysial arteries (internal carotid artery) running in median eminence from hypothalamus
- Venous drainage:
  - to superior and inferior petrosal sinsuses to jugular vein

## **Normal Pituitary Anatomy**



### **Pituitary Disorders**

Anterior pituitary disorders

Posterior Pituitary disorders

### **Anterior Pituitary Disorders**

#### Function:

- Hypersecretion: (GH,LH,FSH,PRL,TSH,ACTH)
- Hyposecretion: hypopituitarism (isolated, multiple, pan)

#### Masses

- Functioning = Hypersecretion
- Non- Functioning
- With /without mass-effect:
  - Space occupying lesion (compression symptoms, hypopituitarism)

## Posterior Pituitary disorders

Diabetes insipidus

# **Anterior Pituitary Function**

	Somatotroph	Gonadotroph	Lactotroph	Thyrotroph	Corticotroph
Stimulators	GHRH GHS	GnRH E2	<b>TRH,</b> E2	TRH	CRH AVP gp-130 cytokines
Inhibitors	IGF-1 Somatostatin Activins	Testosterone, E2 inhibin		T3, T4 Dopamine Somatostatin GH	Steroid
Hormone	GH	LH,FSH	PRL	TSH	ACTH,POMC
Target Gland	Liver & other tissues	Ovary, Testes	Breast & other tissues	Thyroid	Adrenals
Target Hormone	IGF-1	Testosterone, E2		Т4	cortisol
Trophic Effects	IGF-1 production, Growth induction, Insulin antagonism	Sex Steroid Follicular growth Germ Cell maturation	Milk Production	T4 synthesis and secretion	Steroid production Androgen

#### **Pituitary Function**

#### Anterior Pituitary Hormones

- Go Look For The Adenoma Please
- GH , LH, FSH, TSH, ACTH, Prolactin
- A compressive adenoma in pituitary will impair hormone production in this order

#### Posterior Pituitary Hormones

- Oxytocin
- ADH( vasopressin)
- Remember (storage not synthesis)

# **Etiology of Pituitary Masses**

### **Anterior Pituitary Disorders**

#### Function:


- Hypersecretion: (GH,LH,FSH,PRL,TSH,ACTH)
- Hyposecretion: hypopituitarism (isolated, multiple, pan)

#### Masses

- Functioning = Hypersecretion
- Non- Functioning
- With /without mass-effect:
  - Space occupying lesion (compression symptoms, hypopituitarism)

#### **Etiology of Pituitary-Hypothalamic Lesions**

- Non-Functioning Pituitary Adenomas
- Endocrine active pituitary adenomas
  - Prolactinoma (PRL-oma)
  - Somatotropinoma (GH secreting adenoma, Acromegaly)
  - Corticotropinoma (ACTH secreting adenoma, Cushing's disease)
  - Thyrotropinoma (TSH-oma, rare)
  - Other mixed endocrine active adénomas
- Malignant pituitary tumors: Functional and non-functional pituitary carcinoma
- Metastases in the pituitary (breast, lung, stomach, kidney)
- Pituitary cysts: Rathke's cleft cyst, Mucocoeles, Others
- Empty sella syndrome
- Pituitary abscess
- Lymphocytic hypophysitis
- Carotid aneursym







### **Anterior Pituitary Disorders**

#### Function:

- Hypersecretion: (GH,LH,FSH,PRL,TSH,ACTH)
- Hyposecretion: hypopituitarism (isolated, multiple, pan)

#### Masses

- Functioning = Hypersecretion
- Non- Functioning
- With /without mass-effect:
  - Space occupying lesion (compression symptoms, hypopituitarism)

### Disorders of Pituitary Function

#### Hypopituitarism

- Central hypoadrenalism, hypogonadism, hypothyroidism or GH deficiency
- Panhypopituitarism

#### Hypersecretion of Pituitary Hormones

- Hyperprolactinemia
- Acromegaly
- Cushing's Disease

#### **Evaluation of Pituitary mass**

- Pituitary adenoma:
  - 10 % of all pituitary lesions
  - Genetic-related
    - MEN-1, Gs-alpha mutation, PTTG gene, FGF receptor-4
- Pituitary incidentaloma:
  - 1.5 -31 % in autopsy ( prevalence)
  - 10 % by MRI most of them < 1 cm</p>

### **Evaluation of Pituitary lesion**

ANESTH ANALG 2005;101:1170-81 REVIEW ARTICLE NEMERGUT ET AL. TRANSSPHENOIDAL PITUITARY SURGERY

Table 1. Functioning Adenomas: Clinical Disease and Medical Therapy

Clinical disease	Hormone produced by tumor	Estimated frequency (%)	Medical therapy
Acromegaly	Growth hormone	5–10	Somatostatin analog (octreotide) Growth hormone receptor blocker
Cushing's disease	ACTH	10-15	Ketoconazole (blocks cortisol synthesis)
Gonadotroph	FSH, LH	5	None
Prolactinoma	Prolactin	20–30	Dopamine agonist (bromocriptine, cabergoline, pergolide)
Null cell	None	20-25	None
Thyrotropic	TSH	<3	Somatostatin analog (octreotide) Propylthiouracil
Other (including mixed cell adenomas)	None	20	None

ACTH = adrenocorticotropic hormone, FHS = follicle-stimulating hormone, LH = luteinizing hormone, TSH = thyroid-stimulating hormone.

1171

#### **Evaluation of Pituitary lesion**

- C: Clinical (History and Examination)
  - function ( oversection or hyposecretion )
  - Mass ( headache, visual symptoms )
- B: Biochemical
  - Screen Test
  - Confirmatory Test
- A: Anatomical
  - MRI of sella turcica
- Then treatment:
  - Surgical Medical Radiation
  - Medical Surgical Radiation

### Non-functional pituitary adenoma

C: Clinical	Asymptomtic, incidentaloma by imaging Mass-effect (mechanical pressure, hypopituitarism, visual ( bitemproal hemianopia) Gonadal hypersecretion	
B: Biochemical	GH,LH,FSH,TSH,ACTH: not high PRL: low,high, normal	
A: Anatomical	MRI	
Treatment	Surgery if indicated Observation Adjunctive therapy: - Radiation therapy - Dopamine agonist - Somatostatin analogue	

#### Non-functional pituitary adenoma

Y. Greenman, N. Stern / Best Practice & Research Clinical Endocrinology & Metabolism 23 (2009) 625-638


**Table 2** Clinical characteristics of NFPA patients.

	Nomikos et al <sup>15</sup>	Losa et al <sup>16</sup>	Chang et al <sup>17</sup>	Ferrante et al <sup>51</sup>	Total
Number of patients	721	491	663	295	2170
Mean age	$54.2 \pm 19$	-	53 (median)	$\textbf{50.4} \pm \textbf{14.1}$	
Gender (M/F)	401/320	276/215	394/269	161/134	1232/938 (56.7% M)
Incidental finding	57 (7.9%)	57 (11.6%)	49 (7.4%)	_	163/1875 (8.7%)
Headaches	70 (9.7%)	-	212 (32%)	122 (41.4%)	404/1679 (24%)
Visual deficits	222 (30.8%)	287/486 (59.1%)	327 (49%)	200 (67.8%)	1036/2170 (47.7%)
Pressure on cranial nerves	_	22 (4.5%)	26 (3.9%)	-	48/1154 (4.2%)
Apoplexy	27 (3.7%)	48 (9.8%)	24 (3.6%)	-	99/1875 (5.3%)
Symptoms of	345 (47.8%)	_	342 (51.6%)	118 (40%)	805/1679 (48%)
Hypopituitarism					
Documented					
Hypopituitarism	614 (85%)		-	183 (62%)	797/1016 (78.4%)
Hypogonadism	512/659 (77.7%)	335/474 (70.7%)		128 (43.3%)	975/1261 (77.3%)
Hypoadrenalism	230 (31.9%)	115/478 (24.1%)		77 (26.2%)	422/1494 (28.2%)
Hypothyroidism	129/658 (19.6%)	116/462 (25.1%)		72 (24.5%)	317/1415 (22.4%)
Hyperprolactinemia	199 (27.6%)	251/462 (54.3%)	-	82 (27.6%)	532/1478 (35.9%)

627

# Functional pituitary mass

## Prolactin




#### **Prolactin - Low**

 No clinical significant if there is no mass invading the hypothalamus.

- N.B.:
  - PRL is the only pituitary hormone that is inhibited by hypothalamus.

## Prolactinoma (Mass + high level)




#### **Prolactinomas**

1 101000111011100		
C: Clinical	oligomenorrhea, amenorrhea or infertility Galactorrhea Mass-effect ( mechanical pressure, hypopituitarism) Sexual dysfunction (in male)  asleep, stress, pregnancy, lactation and chest wall stimulation or trauma, Renal failure, Liver failure Medication hypothyroid  O/E: Visual field defect ( Bitemporal hemianopia) Nipple discharge	
B: Biochemical	GH,LH,FSH,TSH,ACTH: normal or low PRL: High TSH: R/O Hypothyroidism( primary) IGF-1: R/O acromegaly co-secrtion	
A: Anatomical	MRI	
Treatment	Medical – Medical ( Dopamine agonist) Surgical- Radiation	

#### Prolactinomas

- Most common of functional pituitary adenomas
- 25-30% of all pituitary adenomas
- Some growth hormone (GH)—producing tumors also co-secrete PRL
- Prolactinomas women:
  - 90% present with <u>microprolactinomas</u>
- Prolactinomas in men :
  - 60% present with macroprolactinomas

#### Growth hormone disorder



### Growth hormone deficiency


- Isolated, pan hypopituitarism
- Pituitary tumor as mass effect →→ Growth hormone deficiency

- Disease :
  - Children: Short stature
  - Adult: ??

### Growth hormone deficiency




Diagnosis in children and adult




#### Growth hormone deficiency

C: Clinical	Function : Short stature  Mass-effect ( mechanical pressure, hypopituitarism)
B: Biochemical	Pituitary Function (LH,FSH.PRL, TSH, ACTH, cortisol, testesterone, T4) Screen: IGF-1 Dynamic testing:     clonidine stimulation test     glucagon stimulation     exercise testing,     arginine-GHRH     insulin tolerance testing
A: Anatomical	X-ray of hands: delayed bone age MRI
Treatment	GH replacement


# Acromegaly







# Growth hormone - Acromegaly



# Growth hormone - Acromegaly

Table 1	. Clinical	<b>Features</b>	of A	cromegaly.
---------	------------	-----------------	------	------------

Local tumor effects

Pituitary enlargement

Visual-field defects

Cranial-nerve palsy

Headache

Somatic systems

Acral enlargement, including thickness of soft tissue of hands and feet

Musculoskeletal system

Gigantism

Prognathism

Jaw malocclusion

Arthralgias and arthritis

Carpal tunnel syndrome

Acroparesthesia

Proximal myopathy

Hypertrophy of frontal bones

Skin and gastrointestinal system

Hyperhidrosis

Oily texture

Skin tags

Colon polyps

Cardiovascular system

Left ventricular hypertrophy

Asymmetric septal hypertrophy

Cardiomyopathy

Hypertension

Congestive heart failure

Pulmonary system

Sleep disturbances

Sleep apnea (central and obstructive)

Narcolepsy

Visceromegaly

Tongue

Thyroid gland

Salivary glands

Liver

Spleen

Kidney

Prostate

Endocrine and metabolic systems

Reproduction

Menstrual abnormalities

Galactorrhea

Decreased libido, impotence, low levels of sex hormone-

binding globulin

Multiple endocrine neoplasia type 1

Hyperparathyroidism

Pancreatic islet-cell tumors

Carbohydrate

Impaired glucose tolerance

Insulin resistance and hyperinsulinemia

Diabetes mellitus

Lipid

Hypertriglyceridemia

Mineral

Hypercalciuria, increased levels of 25-hydroxyvitamin D<sub>3</sub>

Urinary hydroxyproline

Electrolyte

Low renin levels

Increased aldosterone levels

Thyroid

Low thyroxine-binding-globulin levels

Goiter

#### Acromegaly

C: Clinical	Function: Sweating, Enlargement (acral, face gross features, heart, tongue Jaw, gigantism in children, Galactorrhea  Mass-effect (mechanical pressure, hypopituitarism)  HTN,CHF, OSA,constipation  O/E: Visual field defect (Bitemporal hemianopia)  Gross features of Acromegaly
B: Biochemical	Pituitary Function (LH,FSH.PRL, TSH, ACTH, cortisol, testesterone, T <sub>4</sub> ) Screen: IGF-1 Confirmatory Test: 75 g OGTT tolerance test for GH suppression

Fasting and random blood sugar, HbA1c Lipid profile


A: Anatomical MRI Echo: Cardiac disease is a major cause of morbidity and mortality 50 % died before age of 50 HTN in 40%, LVH in 50%, Diastolic dysfunction as an early sign of cardiomyopathy

**Treatment** Surgical – Medical (Somatostatin analogue) - Radiation

### **ACTH-disorders**



Hypothalamic or pituitary dysfunction No mineralcorticoid defect



#### Primary Adrenal Insufficiency:

Adrenal dysfunction


Mineralcorticoid defect

High K+

Salt craving

#### **HPA-axis**

- Circadian rhythm of cortisol secretion
- Early morning cortisol between 8-9 am



# **ACTH-disorders**



# Cortisol low (Hypoadrenalism)


- Nausea, Vomiting, abdominal pain, Diarrhea
- Dizziness and weakness, Tiredness, Muscle ache
- Hypotension
- Weight loss



## Management of hypoadrenalism

Cortisol replacement


# HPA-axis (excessive cortisol)



### **ACTH-Adenoma**



# excessive cortisol (Cushing's) Hirsutism in women



# excessive cortisol (Cushing's) Stria (purple, wide >1cm)



HIV Web Study (www.HIV/webstudy.org)

Supported by MRSA

# excessive cortisol (Cushing's)



# excessive cortisol (Cushing's) ecchymosis



### **HPA-axis** (excessive cortisol)

- 80 % HTN
- LVH
- Diastolic dysfunction, intraventricular septal hypertrophy
- ECG needed: high QRS voltage, inverted T-wave
- Echocardiogram preop
- OSA: 33% mild, 18% severe. Needs respiratory assessment and careful use of sedative during surgery
- Glucose intolerance in 60%, control of hyperglycemia
- Osteoporosis with vertebral fracture → → positioning of patient in OR ( 50 %), 20 % with fracture
- thin skin→→ difficult IV cannulation, poor wound healing

#### Cushing's (excessive cortisol)

C: Clinical	Function: Hirsutism, acne, easily bur DM,HTN, irregular period, proximal weakness, recurrent infections, depression O/E: hirsutism, acne, moon face, central obesity, stria, proximal weakness, supraclavicular fat pad,
B: Biochemical	High cortisol, high ACH  24hrs for UFC  1MG DST  Midnight salivary cortisol
A: Anatomical	MRI
Treatment	Surgical – Medical - Radiation

# TSH-Hypothyroid






## Central Hypothyroidism

- Low TSH
- Low free T<sub>4</sub> and T<sub>3</sub>

#### Signs and Symptoms of HYPOTHYROIDISM




#### Central Hypothyroidism

C: Clinical	Function: fatigue, weight gain, irregular menses, dry skin, depression, cold intolerance, increase sleep, slow thinking O/E: obesity,? Depressed face, eye brow
B: Biochemical	Low T4, Low TSH
A: Anatomical	MRI
Treatment	Thyroxine replacement Surgical removal of pituitary adenoma if large

# TSH-hyperthyroid





# TSH-Producing adenoma

- Very rare < 2.8 %</p>
- Signs of hyperthyroidism
- High TSH, FT4, FT3
- Treatment preop with anti-thyroid meds
- Surgical resection of adenoma
- Medical therapy: Somatostatin Analogue

# Gonadotroph adenoma vs. menopause and ovarian failure


- High FSH with low LH
- High serum free alpha subunit
- High estridiol, FSH, thickened endometrium and polycystic ovaries

# Gonadotroph Adenoma

- Surgical resection if large
- Radiation therapy

# Central Diabetes Insipidus

- Polydipsia and Polyuria (2-15 Liters/day)
- Abrupt onset
- 30-50% are idiopathic
  - Dec. production by hypothalamus
- Surgery or Trauma
- Rare with Sheehan's
  - Mild, undetectable degree



#### Dx of Central DI

- Water Deprivation test:
  - Restrict p.o. fluids or administer hypertonic saline to increase serum osmolality to 295-300 mosmol/kg (nml: 275-290)
  - Central DI: urine osmolality still low and returns to normal after administer vasopressin
  - Nephrogenic DI: exogenous vasopressin does not alter urine osmolality much

# Treatment of Central D.I.


- DDAVP (Desmopressin Acetate)
  - Synthetic analog
  - Not catabolized by vasopressinase
  - No vasopressor action
  - Administered intranasally (rec.) or p.o.
  - Titrate 10-20ug qd or bid
  - Safe in pregnancy and breastfeeding

NDC 0075-2452-01 DDAVP Nasal Spray (desmopressin acetate) 0.01% NASAL SOLUTION New Formulation -Needs No Refrigeration

5 mL (50 doses of 10 μg)



Attention Pharmacistdetach patient's instructions from package insert and dispense with spray pump.



# assessment of pituitary function

- Baseline: TSH, FT4, FT3, LH, FSH, Prolactin, GH, IGF-I,Testosterone, Estradiol
- MRI brain
- Neuropthalmic evaluation of visual field
- Cardiac and respiratory assessment
- Anesthesiologist for airway and perioperative monitoring
- Neurosurgeon
- ENT for Endonasal evaluation for surgical approach
- Preop hormonal replacement: all pituitary adenoma should be covered with stress dose of HC